foxo4 dri senolytic 2023 2024 Targeting Cellular Senescence in Aging and Age-Related Diseases: Challenges, Considerations, and the Emerging Role of and Senomorphic Therapies The disordered p53 transactivation domain
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI improves spermatogenesis in aged mice through reducing senescence associated secretory phenotype secretion from Leydig cells ScienceDirect Immunofluorescence reveals the effect of FOXO4 D Retro Inverso on p53 Download Scientific Diagram Senolytic Drugs Market to Reach USD 667.6 Million by 2033
Pay in 4 interest-free payments of $5.64 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6



